Your browser doesn't support javascript.
loading
Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleeding.
Cao, Davide; Amabile, Nicolas; Chiarito, Mauro; Lee, Victoria T; Angiolillo, Dominick J; Capodanno, Davide; Bhatt, Deepak L; Mack, Michael J; Storey, Robert F; Schmoeckel, Michael; Gibson, C Michael; Deliargyris, Efthymios N; Mehran, Roxana.
Afiliación
  • Cao D; Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574, USA.
  • Amabile N; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy.
  • Chiarito M; Department of Cardiology, Humanitas Gavazzeni, Bergamo, Italy.
  • Lee VT; Department of Cardiology, Institut Mutualiste Montsouris, Paris, France.
  • Angiolillo DJ; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy.
  • Capodanno D; Department of Cardiology, IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy.
  • Bhatt DL; PAVmed Inc., New York, NY, USA.
  • Mack MJ; Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA.
  • Storey RF; Division of Cardiology, Azienda Ospedaliero Universitaria Policlinico 'G. Rodolico-San Marco', University of Catania, Catania, Italy.
  • Schmoeckel M; Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Gibson CM; Department of Cardiac Surgery, Baylor Scott and White Health, Plano, TX, USA.
  • Deliargyris EN; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
  • Mehran R; Department of Cardiac Surgery, Asklepios Klinik St. Georg, Hamburg, Germany.
Eur Heart J ; 44(20): 1780-1794, 2023 05 21.
Article en En | MEDLINE | ID: mdl-36988155
ABSTRACT
Remarkable progress has been made in the pharmacological management of patients with cardiovascular disease, including the frequent use of antithrombotic agents. Nonetheless, bleeding complications remain frequent and potentially life-threatening. Therapeutic interventions relying on prompt antithrombotic drug reversal or removal have been developed to assist clinicians in treating patients with active bleeding or an imminent threat of major bleeding due to urgent surgery or invasive procedures. Early phase studies on these novel strategies have shown promising results using surrogate pharmacodynamic endpoints. However, the benefit of reversing/removing antiplatelet or anticoagulant drugs should always be weighed against the possible prothrombotic effects associated with withdrawal of antithrombotic protection, bleeding, and surgical trauma. Understanding the ischemic-bleeding risk tradeoff of antithrombotic drug reversal and removal strategies in the context of urgent high-risk settings requires dedicated clinical investigations, but challenges in trial design remain, with relevant practical, financial, and ethical implications.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Fibrinolíticos Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Fibrinolíticos Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article